中度から重度まで活発な潰瘍性大腸炎 (QUASAR) の患者におけるグセルクマブ:第3段階のダブルブラインド,ランダム化,プラセボ対照誘導および維持試験
David T Rubin1, Jessica R Allegretti2, Julián Panés3
1University of Chicago Medicine Inflammatory Bowel Disease Centre, Chicago, IL, USA.
Lancet (London, England)
|December 20, 2024
まとめ
グセルクマブは,中度から重度の活発な潰瘍性大腸炎の成人に効果的に寛解を誘導し,維持しました. このインタールイキン-23阻害剤は,第3相試験で好ましい安全性プロファイルを示し,新しい治療選択肢を提供しました.
科学分野:
- 胃腸内科
- 免疫学
- 薬理学について
背景:
- 潰瘍性大腸炎 (UC) は慢性炎症性腸疾患である.
- インタールイウキン-23 (IL-23) はUCの病原性における重要なサイトカインである.
- IL - 23の抑制はUCの有望な治療戦略として浮上しています.
研究 の 目的:
- 中度から重度のUCの成人患者の寛解を誘発し維持するIL-23p19サブユニット阻害剤の効果と安全性を評価する.
- 3期臨床試験において,グセルクマブの効果をプラセボと比較して評価する.
主な方法:
- 2つのランダム化,ダブルブラインド,プラセボ対照のフェーズ3試験 (QUASAR誘導および維持) が実施された.
- 中度から重度までUCが活発で,以前の治療に不十分な反応を示した成人を対象とした.
- 患者は,誘導のために静脈内ガスルクマブまたはプラセボを投与し,その後,維持のために皮下ガスルクマブまたはプラセボを投与した.
主要な成果:
- グセルクマブは,プラセボと比較して,12週間の臨床寛解率を有意に増加させた (23%対8%,p< 0. 0001).
- 維持段階では,グルセルクマブ投与レジームの両方に対して (45%),プラセボ (19%),p< 0. 0001) で,臨床寛解率が著しく高かった.
- グセルクマブの安全性プロファイルは良好で,既知のプロファイルと一致し,新たな安全性懸念は認められませんでした.
結論:
- グセルクマブは,中度から重度の活発な潰瘍性大腸炎患者の臨床寛解の達成と維持に有意な効果を示した.
- グセルクマブは,この患者集団における誘導および維持療法の安全で効果的な治療法です.
関連する概念動画
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:21Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133